[Treatment of chronic viral hepatitis].
Interferon-alfa is used for the treatment of chronic viral hepatitis. The best results for HCV are obtained with pegylated interferon-alpha in combination with the antiviral drug ribavirin. Sustained response (cure) is obtained in 40% (genotype 1) to 85% (genotype 2 or 3) of treated patients. Interferon-alpha has many side effects, and the selection of patients for treatment should be made taking into consideration the individual prognosis and relative and absolute contraindications. New biologics are in clinical development.
Pedersen
Court
C
Odense Universitetshospital, Infektionsmedicinsk Afdeling Q, Odense C. court.pedersen@ouh.regionsyddanmark.dk
Pedersen
Christian Ross
CR
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D012254:Ribavirin